Sanofi (SNY.US) applies for market approval for new indication of long-acting RSV monoclonal antibody
On August 7, according to the CDE official website, the marketing application for a new indication of Sanofi (SNY.US)'s nirsevimab injection has been accepted, with a registration classification of Category 3.1.
According to Golden Ten Data APP, on August 7, the official CDE website announced that the new indication listing application for Sanofi (SNY.US)'s Nirsevimab Injection has been accepted, with a registration classification of category 3.1. Based on publicly available information and clinical trial progress, the Insight database speculates that the indication for this application is the prevention of lower respiratory tract infection caused by respiratory syncytial virus (RSV) in infants and young children: specifically, newborns and infants entering or born during their second RSV season.
Nirsevimab is a single-dose, long-acting monoclonal antibody vaccine developed jointly by Sanofi and AstraZeneca. With just one dose, it provides rapid protection against RSV-induced lower respiratory tract diseases through antibodies, without needing to activate the immune system.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
UBS lowers Ciena target price to $394
EUR/USD Price Forecast: Holds key 100-day SMA at start of the US CPI week
Malaysia Govt Spending Plan Could Help 99 Speed Mart Retail -- Market Talk
Paying the price for supporting the yen? Japan's foreign reserves fell by $87.8 billions in August, possibly due to selling US Treasuries for funding.
Japanese authorities may have used part of their foreign exchange reserves, including foreign securities such as U.S. Treasury bonds, over the past month to fund record-sized foreign exchange intervention operations.
Crypto prices
More
